Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulation

Leuk Lymphoma. 2015;56(9):2714-6. doi: 10.3109/10428194.2014.1003061. Epub 2015 Feb 17.

Authors

Simon McAuliffe^{1

2}, Ross Brown¹, Alberto Catalano¹, P Joy Ho¹, Najah Nassif², Narelle Woodland², Derek Hart³, Claire Weatherburn¹, Shihong Yang¹, Hayley Suen^{1

2}, Cheryl Paul¹, Douglas Joshua¹, John Gibson¹

Affiliations

¹ a Institute of Haematology, Royal Prince Alfred Hospital , Sydney , Australia.
² b School of Medical and Molecular Biosciences, University of Technology , Sydney , Australia.
³ c Dendritic Cell Biology and Therapeutics Group, ANZAC Research Institute, Concord Hospital , Sydney , Australia.

PMID: 25651422
DOI: 10.3109/10428194.2014.1003061

No abstract available

Publication types

Letter

MeSH terms

Biomarkers, Tumor
Genes, abl
Humans
Multiple Myeloma / diagnosis*
Multiple Myeloma / genetics*
Neoplasm, Residual / diagnosis*
Neoplasm, Residual / genetics*
Polymerase Chain Reaction* / methods
Receptor, Fibroblast Growth Factor, Type 3 / genetics*

Substances

Biomarkers, Tumor
Receptor, Fibroblast Growth Factor, Type 3